Matica Bio, VaxDome partner on antiviral hybrid vaccine development

Matica Biotechnology, the US contract development and manufacturing organization subsidiary of CHA Biotech, has partnered with Texas-based VaxDome Inc. to jointly develop an antigen-agnostic antiviral vaccine aimed at protecting against a broad range of infectious diseases.

The collaboration will focus on advancing VaxDome's hybrid antiviral vaccine candidates into clinical trials.

Under the agreement, Matica Biotechnology will provide process development, analytical development and the producti ...